Lifecycle ManagementNarrow moat

Drugmakers do not simply wait for their patents to expire; they actively work to extend the commercial life of a franchise through what the industry calls lifecycle management — a set of strategies for stretching protection and revenue before the clock runs out. New formulations, new delivery methods, new approved uses, combination products, and follow-on patents can all lengthen the effective monopoly or soften the eventual cliff, and skilled lifecycle management can add years of profitable life to a valuable drug.

For Lilly, this is a genuine and repeatedly-demonstrated capability. The tirzepatide molecule is itself a case study¹: sold as Mounjaro for diabetes and Zepbound for obesity, extended toward new indications like sleep apnea and heart failure, and developed in new forms — each approved use widens the market and can extend protection. Winning additional indications for an existing drug is one of the most capital-efficient things a pharma company can do, since the molecule is already proven and the incremental trials are cheaper than discovering something new.

The honest limit is that lifecycle management delays the cliff rather than abolishing it, and its tactics face growing scrutiny — regulators and critics increasingly challenge patent strategies they view as gaming the system to block generic competition. So lifecycle management is a real, valuable skill that extends and enlarges Lilly's franchises and buys time for the pipeline, but it is a way of managing the temporary nature of patents, not escaping it. The clock can be slowed and the franchise widened, but the fundamental fact — that the monopoly ends — remains.